Journey Medical (NASDAQ:DERM) Announces Earnings Results, Misses Expectations By $0.03 EPS

Journey Medical (NASDAQ:DERM) posted its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Yahoo Finance reports. The business had revenue of $14.86 million during the quarter, compared to analyst estimates of $13.81 million. Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. During the same period in the prior year, the firm posted ($0.46) EPS.

Journey Medical Price Performance

Shares of NASDAQ DERM traded up $0.33 during trading on Tuesday, reaching $4.55. 17,052 shares of the stock traded hands, compared to its average volume of 135,574. Journey Medical has a 52-week low of $1.78 and a 52-week high of $8.11. The stock has a market cap of $91.06 million, a PE ratio of -14.68 and a beta of 0.93. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94. The firm has a 50-day moving average of $5.30.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Roth Mkm began coverage on Journey Medical in a research report on Friday, June 28th. They set a “buy” rating and a $11.00 target price for the company. Roth Capital upgraded shares of Journey Medical to a “strong-buy” rating in a research report on Friday, June 28th.

Insider Activity

In other Journey Medical news, CFO Joseph Benesch sold 9,324 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $5.47, for a total value of $51,002.28. Following the transaction, the chief financial officer now directly owns 47,331 shares in the company, valued at approximately $258,900.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.42% of the stock is owned by company insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.